Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Pays $1.25bn For Peace Of Mind Over Tecfidera, But Legal Wrangling Continues

Executive Summary

Biogen's new CEO Michel Vounatsos has begun his tenure by taking out a $1.25bn "insurance policy" on MS drug Tecfidera by licensing Forward Pharma's patent portfolio, but the cost of the deal could spiral if the Danish firm wins a series of ongoing patent disputes with Biogen concerning Tecfidera and Forward Pharma's MS drug candidate FP187.

You may also be interested in...



Deals Of The Year: Cast Your Vote For Top Alliance Of 2017

It's time for In Vivo's10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.) First up, the top five picks for most significant strategic alliance of 2017.

Forward Pharma Faces Uphill Struggle Appealing Biogen's Tecfidera PTAB Win

Forward Pharma is suspending all FP187 development pending the outcome of its legal interference appeal against Biogen – but analysts see little prospect of it overturning last month's decision that effectively allows Biogen's dimethyl fumarate-based drug Tecfidera to stay on the market with its own patent.

Biogen Secures First-Round Patent Win For Tecfidera; One More To Go

PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098061

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel